Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) shares traded up 8.7% during trading on Tuesday . The company traded as high as $20.16 and last traded at $19.94. 301,071 shares changed hands during trading, an increase of 211% from the average session volume of 96,751 shares. The stock had previously closed at $18.35.
Analyst Upgrades and Downgrades
Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx Biosciences in a research report on Thursday, May 15th.
Read Our Latest Report on Inhibrx Biosciences
Inhibrx Biosciences Trading Up 2.8%
The stock has a 50-day simple moving average of $13.91 and a 200 day simple moving average of $13.54. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 1.04. The company has a market cap of $311.31 million, a price-to-earnings ratio of 0.18 and a beta of -0.04.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($2.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). As a group, equities research analysts predict that Inhibrx Biosciences, Inc. will post 104.88 EPS for the current fiscal year.
Hedge Funds Weigh In On Inhibrx Biosciences
Institutional investors have recently modified their holdings of the stock. Strs Ohio purchased a new position in shares of Inhibrx Biosciences during the 1st quarter valued at about $27,000. PNC Financial Services Group Inc. purchased a new position in shares of Inhibrx Biosciences in the 4th quarter valued at about $28,000. Natixis purchased a new position in shares of Inhibrx Biosciences in the 4th quarter valued at about $31,000. State of Wyoming purchased a new stake in Inhibrx Biosciences during the 4th quarter worth approximately $83,000. Finally, Corebridge Financial Inc. purchased a new stake in Inhibrx Biosciences during the 4th quarter worth approximately $89,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
Inhibrx Biosciences Company Profile
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Articles
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
